Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.5glegtPn.js ...
Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...
Johnson & Johnson’s medtech leader said Wednesday that the company is now working with the Food and Drug Administration about safety risks tied to its Varipulse pulsed field ablation device.
Opens in a new tab or window Just months after FDA approval, Johnson & Johnson paused the rollout of its Varipulse pulsed field ablation (PFA) platform in the U.S. due to safety reasons.
All ablation cases set to use the Varipulse pulsed-field ablation (PFA) system have been temporarily halted in the United States after four neurovascular events were reported during an external ...
“Out of an abundance of caution,” Johnson & Johnson MedTech has temporarily paused the use of its Varipulse field ablation system in the United States, the company announced. The move comes ...
Johnson & Johnson halted U.S. Varipulse cases after four reported neurovascular events during external evaluation trials. Over 130 U.S. cases and 3,000 global commercial cases have been performed ...
Johnson & Johnson (NYSE: JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets ...
Johnson & Johnson MedTech announced that it has halted U.S. procedures and sales of its recently approved Varipulse pulsed field ablation system following reports of four patient strokes.
Jan 8 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday it had temporarily paused the rollout of its Varipulse heart device in the United States, as the company investigates ...
Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...